HUE037575T2 - Gyógyászati kompozíció, amely tartalmaz egy HDAC (hiszton deacetiláz) inhibitort és egy ciklopoliszacharidot - Google Patents
Gyógyászati kompozíció, amely tartalmaz egy HDAC (hiszton deacetiláz) inhibitort és egy ciklopoliszacharidotInfo
- Publication number
- HUE037575T2 HUE037575T2 HUE12831417A HUE12831417A HUE037575T2 HU E037575 T2 HUE037575 T2 HU E037575T2 HU E12831417 A HUE12831417 A HU E12831417A HU E12831417 A HUE12831417 A HU E12831417A HU E037575 T2 HUE037575 T2 HU E037575T2
- Authority
- HU
- Hungary
- Prior art keywords
- cyclopolysaccharide
- pharmaceutical composition
- hdac inhibitor
- hdac
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161536038P | 2011-09-18 | 2011-09-18 | |
US201261602408P | 2012-02-23 | 2012-02-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE037575T2 true HUE037575T2 (hu) | 2018-09-28 |
Family
ID=47883974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE12831417A HUE037575T2 (hu) | 2011-09-18 | 2012-09-14 | Gyógyászati kompozíció, amely tartalmaz egy HDAC (hiszton deacetiláz) inhibitort és egy ciklopoliszacharidot |
Country Status (40)
Country | Link |
---|---|
US (1) | US9376395B2 (hu) |
EP (2) | EP2758052B9 (hu) |
JP (2) | JP2014526512A (hu) |
KR (2) | KR20140078619A (hu) |
CN (1) | CN103826630B (hu) |
AP (1) | AP3656A (hu) |
AR (1) | AR087909A1 (hu) |
AU (1) | AU2012308453B2 (hu) |
BR (1) | BR112014006271B1 (hu) |
CA (1) | CA2847842C (hu) |
CL (1) | CL2014000645A1 (hu) |
CO (1) | CO6930367A2 (hu) |
CR (1) | CR20140134A (hu) |
CY (1) | CY1120080T1 (hu) |
DK (1) | DK2758052T3 (hu) |
DO (1) | DOP2014000048A (hu) |
EA (1) | EA028413B1 (hu) |
EC (1) | ECSP14013239A (hu) |
ES (2) | ES2662775T3 (hu) |
GT (1) | GT201400069A (hu) |
HK (2) | HK1199824A1 (hu) |
HR (1) | HRP20180690T1 (hu) |
HU (1) | HUE037575T2 (hu) |
IL (1) | IL230838A (hu) |
LT (1) | LT2758052T (hu) |
ME (1) | ME03088B (hu) |
MX (1) | MX346432B (hu) |
MY (1) | MY169495A (hu) |
NI (1) | NI201400022A (hu) |
NZ (1) | NZ621386A (hu) |
PE (1) | PE20141552A1 (hu) |
PL (1) | PL2758052T3 (hu) |
PT (1) | PT2758052T (hu) |
RS (1) | RS57063B1 (hu) |
SI (1) | SI2758052T1 (hu) |
TN (1) | TN2014000095A1 (hu) |
TW (1) | TWI583382B (hu) |
UA (1) | UA116333C2 (hu) |
WO (1) | WO2013040286A2 (hu) |
ZA (1) | ZA201401676B (hu) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR092790A1 (es) | 2012-02-01 | 2015-05-06 | Euro Celtique Sa | Derivados bencimidazolicos del acido hidroxamico |
US20150087687A1 (en) | 2012-03-23 | 2015-03-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
CA2925546C (en) | 2012-10-29 | 2022-06-14 | The University Of North Carolina At Chapel Hill | Methods and compositions for treating mucosal tissue disorders |
GB201409471D0 (en) * | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409488D0 (en) * | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
JP2017537164A (ja) * | 2014-12-05 | 2017-12-14 | ユニヴァーシティ・オブ・モデナ・アンド・レッジョ・エミリア | リンパ腫の治療に使用されるヒストン脱アセチル化酵素阻害剤とベンダムスチンとの組み合わせ |
CN106580971B (zh) * | 2015-10-20 | 2019-11-12 | 杭州梯诺医药科技有限公司 | 一种药物组合物及其制备方法 |
EP4321513A3 (en) | 2016-03-28 | 2024-05-08 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
US11266631B2 (en) | 2016-10-11 | 2022-03-08 | Purdue Pharmaceutical Products L.P. | Hodgkin lymphoma therapy |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
GB201709405D0 (en) * | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
JP6770986B2 (ja) | 2018-03-06 | 2020-10-21 | 日本電産モビリティ株式会社 | 誘導性負荷制御装置 |
MX2021000127A (es) | 2018-06-29 | 2021-03-29 | Incyte Corp | Formulaciones de un inhibidor de axl/mer. |
CA3124005A1 (en) * | 2018-12-18 | 2020-06-25 | Mundipharma International Corporation Limited | Compounds for treating multiple myeloma |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376A (en) | 1847-11-20 | Improvement in bog-cutters | ||
US645A (en) | 1838-03-17 | Back for poeges and fetrnages | ||
DE34727C (de) | Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue | Verfahren zur direkten Gewinnung metallischen Bleis | ||
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9126209D0 (en) | 1991-12-10 | 1992-02-12 | Orion Yhtymae Oy | Drug formulations for parenteral use |
US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
AU750207B2 (en) | 1997-06-13 | 2002-07-11 | Cydex Pharmaceuticals, Inc. | Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof |
AU2004215624B2 (en) | 2003-02-25 | 2011-06-02 | Topotarget Uk Limited | Hydroxamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors |
EA018982B1 (ru) * | 2005-05-13 | 2013-12-30 | Топотаргет Юкей Лимитед | Фармацевтические составы, содержащие ингибиторы деацетилазы гистонов |
WO2008067027A2 (en) * | 2006-10-20 | 2008-06-05 | Icos Corporation | Compositions of chkl inhibitors and cyclodextrin |
WO2009100045A1 (en) | 2008-02-04 | 2009-08-13 | Translational Genomics Research Institute | Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives |
EP2326306A1 (en) * | 2008-09-25 | 2011-06-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
CN102186842B (zh) * | 2009-01-23 | 2014-07-23 | 杭州民生药业有限公司 | 异羟肟酸衍生物 |
JP5654498B2 (ja) * | 2009-02-25 | 2015-01-14 | スプラテック ファーマ インコーポレイテッド | ベンダムスチン環状多糖組成物 |
CN101928234B (zh) * | 2010-01-15 | 2012-12-12 | 北京欧凯纳斯科技有限公司 | 6/7-(杂)芳基-n-羟基己/庚酰胺化合物及其制备方法 |
JO3659B1 (ar) * | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
CN102993102B (zh) * | 2011-09-16 | 2016-08-24 | 杭州民生药业有限公司 | [1-甲基-2-(7’-庚异羟肟酸基)-5-n,n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法 |
-
2012
- 2012-09-14 CN CN201280044834.1A patent/CN103826630B/zh active Active
- 2012-09-14 AU AU2012308453A patent/AU2012308453B2/en active Active
- 2012-09-14 WO PCT/US2012/055277 patent/WO2013040286A2/en active Application Filing
- 2012-09-14 SI SI201231266T patent/SI2758052T1/en unknown
- 2012-09-14 BR BR112014006271-4A patent/BR112014006271B1/pt active IP Right Grant
- 2012-09-14 PL PL12831417T patent/PL2758052T3/pl unknown
- 2012-09-14 RS RS20180387A patent/RS57063B1/sr unknown
- 2012-09-14 EP EP12831417.6A patent/EP2758052B9/en active Active
- 2012-09-14 ES ES12831417.6T patent/ES2662775T3/es active Active
- 2012-09-14 NZ NZ621386A patent/NZ621386A/en unknown
- 2012-09-14 US US14/345,562 patent/US9376395B2/en active Active
- 2012-09-14 KR KR20147006534A patent/KR20140078619A/ko active Application Filing
- 2012-09-14 PE PE2014000365A patent/PE20141552A1/es active IP Right Grant
- 2012-09-14 MY MYPI2014000622A patent/MY169495A/en unknown
- 2012-09-14 HU HUE12831417A patent/HUE037575T2/hu unknown
- 2012-09-14 UA UAA201404114A patent/UA116333C2/uk unknown
- 2012-09-14 ES ES17208980T patent/ES2911427T3/es active Active
- 2012-09-14 CA CA2847842A patent/CA2847842C/en active Active
- 2012-09-14 KR KR1020197027187A patent/KR102048079B1/ko active IP Right Grant
- 2012-09-14 EP EP17208980.7A patent/EP3318284B1/en active Active
- 2012-09-14 LT LTEP12831417.6T patent/LT2758052T/lt unknown
- 2012-09-14 ME MEP-2018-92A patent/ME03088B/me unknown
- 2012-09-14 DK DK12831417.6T patent/DK2758052T3/en active
- 2012-09-14 AP AP2014007498A patent/AP3656A/xx active
- 2012-09-14 PT PT128314176T patent/PT2758052T/pt unknown
- 2012-09-14 EA EA201490650A patent/EA028413B1/ru unknown
- 2012-09-14 MX MX2014003283A patent/MX346432B/es active IP Right Grant
- 2012-09-14 JP JP2014530810A patent/JP2014526512A/ja active Pending
- 2012-09-17 TW TW101133961A patent/TWI583382B/zh active
- 2012-09-17 AR ARP120103432 patent/AR087909A1/es not_active Application Discontinuation
-
2014
- 2014-02-06 IL IL230838A patent/IL230838A/en active IP Right Grant
- 2014-03-04 DO DO2014000048A patent/DOP2014000048A/es unknown
- 2014-03-06 TN TNP2014000095A patent/TN2014000095A1/en unknown
- 2014-03-06 ZA ZA2014/01676A patent/ZA201401676B/en unknown
- 2014-03-13 EC ECSP14013239 patent/ECSP14013239A/es unknown
- 2014-03-17 CL CL2014000645A patent/CL2014000645A1/es unknown
- 2014-03-17 NI NI201400022A patent/NI201400022A/es unknown
- 2014-03-24 CR CR20140134A patent/CR20140134A/es unknown
- 2014-04-11 CO CO14079713A patent/CO6930367A2/es unknown
- 2014-04-14 GT GT201400069A patent/GT201400069A/es unknown
-
2015
- 2015-01-12 HK HK15100300.8A patent/HK1199824A1/xx unknown
-
2017
- 2017-12-14 JP JP2017239611A patent/JP6557318B2/ja active Active
-
2018
- 2018-03-26 CY CY20181100336T patent/CY1120080T1/el unknown
- 2018-05-03 HR HRP20180690TT patent/HRP20180690T1/hr unknown
- 2018-10-09 HK HK18112837.2A patent/HK1253692A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1253692A1 (zh) | 含有hdac抑制劑和環多醣的藥物組合物 | |
HK1215948A1 (zh) | 醯胺及其醫藥用途 | |
IL253870B (en) | Certain amino-pyrimidines and pharmaceutical preparations containing them | |
EP2771321A4 (en) | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH | |
EP2721031A4 (en) | BROMODOMA INHIBITORS AND ITS USE | |
EP2705039A4 (en) | BROMODOMAIN INHIBITORS AND USES THEREOF | |
HK1189587A1 (en) | Bromodomain inhibitors and uses thereof | |
EP2663312A4 (en) | IRAQ INHIBITORS AND THEIR USE | |
HK1198827A1 (en) | Dyrk1 inhibitors and uses thereof dyrk1 | |
EP2571352A4 (en) | SELECTIVE HDAC HEMMER | |
ZA201307956B (en) | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor | |
EP2623556A4 (en) | DRIP AND RESIN CONNECTION | |
EP2688572A4 (en) | PHARMACEUTICAL COMPOSITION USING A HDAC HEMMER AND STEROID, AND USE THEREOF | |
HK1152485A1 (en) | A pharmaceutical composition comprising l-carnitine and dobesilate | |
ZA201304633B (en) | A pharmaceutical composition | |
EP2775831A4 (en) | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
SI2753313T1 (sl) | Farmacevtski sestavki, ki obsegajo inhibitor aromataze | |
PL2659889T3 (pl) | Kompozycja przeciwgorączkowa/przeciwbólowa | |
HRP20141173T1 (hr) | Medikament koji sadrži miramistin | |
ZA201205684B (en) | Ester compound and use thereof | |
ZA201201003B (en) | A pharmaceutical composition | |
EP2784065A4 (en) | GLYCINE REUPTAKE INHIBITOR AND USE THEREOF | |
GB201110598D0 (en) | Pharmaceutical compositions and devices | |
GB201018597D0 (en) | Inhibitors |